Skip to main content
BCDA logo

BCDA · BioCardia, Inc. · Documents

Track BCDA — free
$0.73 -0.04 (-5.24%) Play latest call Q3 2026 earnings call transcript
Market Cap
$11.70M
Shares
15.14M
Volume · Nov 19 157.43K Avg daily vol (3M) 202.25K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $0 10-K filed Mar 24, 2026 Quarterly report FY2026 Q3 Net loss $1.82M 10-Q filed Nov 12, 2026 Latest results Quarterly net loss rises to $1.8 million as cash reaches $2.2 million 8-K filed Nov 12, 2026 Earnings call Q3 2026 earnings call Held Nov 12, 2026
2026
Nov 12
Earnings call
Japan filing advances with $2.2 million cash and 2027 runway

Biocardia says Japan filing work is progressing, FDA feedback on Helix is expected within six weeks, and a potential de novo submission is targeted for first quarter of 2027. It ended with $2.2 million in cash, providing runway into 2027.

5 source passages
Biocardia is fully committed to the post-marketing study launch in Japan with our expertise, but we do recognize the value that a partner has for long-term growth in Japan and the Asia-Pacific region. We have answered all of these questions to Japan's Pharmaceuticals and Medical Devices Agency satisfaction, and we are proceeding to Shonen's submission with our designated marketing authorization holder. We expect to hear from the FDA on this pre-submission in the next six weeks. If the FDA supports the de novo approval pathway for Helix, we expect to complete the de novo submission in the first quarter of 2027 We ended the quarter with cash and cash equivalents totaling $2.2 million, providing runway into 2027. Open the document at this passage
Nov 12
Current report 8-K
Quarterly net loss rises to $1.8 million as cash reaches $2.2 million

BioCardia reported a $1.8 million net loss for the three months ended September 2026 and ended the quarter with $2.2 million in cash and cash equivalents, providing anticipated runway into 2027.

Financial results
3 source passages
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results Our net loss was $1.8 million for the three months ended September 2026 compared to $1.5 million for the three months ended September 2025. The Company ended the quarter with cash and cash equivalents totaling $2.2 million, providing anticipated runway into 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $2.2 million funds operations only through January 2027

BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.

Net loss $1.82M
Read from the first part of this long document
3 source passages
BioCardia, Inc. (we, us, our, BioCardia or the Company), is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Therefore, absent additional funding, management believes our cash and cash equivalents of approximately $2.2 million as of September 30, 2026 are not sufficient to fund our planned expenditures and meet our obligations beyond January 2027. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. Open the document at this passage
Nov 6
Current report 8-K
CardiAMP advances toward Japanese marketing application

BioCardia completed consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), advancing the CardiAMP Cell Therapy System toward a marketing approval application in Japan. Completion does not constitute regulatory approval, and PMDA review remains outstanding.

Other events
2 source passages
BioCardia® , Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System ("CardiAMP") for the treatment of ischemic heart failure. Completion of the consultation process does not constitute regulatory approval. The CardiAMP Cell Therapy System remains subject to PMDA review and applicable Japanese regulatory requirements. Open the document at this passage
Oct 19
Current report 8-K
Other events

BioCardia announced the FDA accepted its De Novo pre-submission package for marketing clearance of the Helix catheter, with substantive review and a meeting expected this quarter.

Oct 7
Current report 8-K
Other events

BioCardia announced the CardiAMP HF II trial design for presentation at the Heart Failure Society of America Annual Scientific Meeting 2026; FDA said the ongoing trial may support approval.

Oct 1
Current report 8-K
Other events

BioCardia completed its revised De Novo Pre-Submission seeking FDA approval of the Helix Catheter for agent delivery to the heart. FDA identified two marketing-clearance pathways and raised no concerns about safety data, device performance, or agent compatibility.

Sep 23
Current report 8-K
Other events

BioCardia targets a Q4 2026 PMDA Shonin submission for CardiAMP, which could result in market clearance by Q4 2027, and plans a Helix follow-on De Novo pre-submission this quarter.

Sep 21
Current report 8-K
Other events

BioCardia regained compliance with Nasdaq’s $1.00 per share minimum bid price requirement after its closing bid price remained at $1.00 per share or greater for at least 10 consecutive business days. The matter is closed, and BCDA continues trading on The Nasdaq Capital Market.

Sep 10
Current report 8-K
Other events AI summary on its way
Jun 8
Current report 8-K
Other events AI summary on its way
Apr 28
Current report 8-K
Other events AI summary on its way
Mar 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $0 Net loss $8.23M
Mar 17
Current report 8-K
Other events AI summary on its way
Feb 10
Current report 8-K
Other events AI summary on its way
Feb 3
Current report 8-K
Other events AI summary on its way
2025
Showing 1–50 of 259 documents
Key facts CIK 925741 CUSIP 09060U606 13F (30d) 21 filings 21 filers Visit website Investor relations